Recurrent syncope with a type 1 Brugada ECG pattern in a patient on amitriptyline: Brugada syndrome versus phenocopy − a case report

Clicks: 12
ID: 329915
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #323 of 408 articles by views in European Heart Journal - Case Reports

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 408 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Brugada syndrome is an inherited arrhythmogenic channelopathy associated with an increased risk of sudden cardiac death. Diagnosis relies on the presence of a spontaneous type 1 Brugada pattern on electrocardiogram (ECG). While multiple hypotheses have been proposed to explain its underlying mechanism, it is generally thought to be secondary to defective myocardial sodium channels. For this reason, sodium channel-blocking medications can induce a type 1 Brugada pattern, which may complicate risk stratification and raise the possibility of Brugada phenocopy. Case summary A 44-year-old man on regular amitriptyline 75 mg for anxiety and panic disorder, presented with two episodes of syncope. ECG showed classical features of a type 1 Brugada pattern. Routine blood investigations, including full blood count, renal function tests, a comprehensive electrolyte panel and high-sensitivity troponin were normal. Transthoracic echocardiography revealed normal cardiac structure and function. Following multidisciplinary team (MDT) discussion, and guided by the 2022 European Society of Cardiology (ESC) guidelines, a shared decision was made to proceed with implantable cardioverter-defibrillator (ICD) implantation. The patient was discharged with follow-up in the arrhythmia clinic and referred for genetic testing. Discussion This case highlights the diagnostic and management challenges of differentiating true Brugada syndrome from drug-induced Brugada phenocopy. Although the presence of a type 1 Brugada ECG pattern in our patient occurred in the context of amitriptyline use, his presentation with syncope complicates risk stratification. MDT discussion and reference to ESC guidelines played a key role in determining further management, which in this case was ICD implantation.
Reference Key
openalex_W7214484774 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Muhammad Khairul Asyraf, Philip Smyth, Sajjad Matiullah
Are you one of these authors? Claim your profile
Journal European Heart Journal - Case Reports
Year 2026
DOI
10.1093/ehjcr/ytag710
URL
https://doi.org/10.1093/ehjcr/ytag710
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.